Same opinion here. Several valuable patents, giving them access to the market for rare diseases. Further, they already had the success with FDA on their product, and started to commercialize it in the market.

What's more, there is a good chance a few bigger companies in pharmaceuticals can be targeting AUPH for an acquisition. As mentioned before, an interesting portfolio of patents which might be interesting for those companies to increase the market coverage.